MMRi6
MMRi6 is a Mdm2-MdmX RING domain inhibitor that can disrupt Mdm2-MdmX RING-RING interaction in vitro. MMRi6 inhibits MdmX-stimulated Mdm2 autoubiquitination and Mdm2-MdmX-mediated p53 polyubiquitination in vitro without affecting NEDD4-1 autoubiquitination. MMRi6 induces p53 stabilization and accumulation and induces PARP cleavage in wt-p53 Emu-myc lymphoma cells. MMRi6 inhibits the growth of wt-p53 and p53-null Emu-myc lymphoma cells with IC50s of approximately 0.5 μM and 3 μM, respectively. MMRi6 can be used for the study of leukemia/lymphoma[1].
Product Specifications
CAS Number
[709009-15-4]
UNSPSC
12352005
Target
MDM-2/p53; PARP
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.70
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC1=C2N=CC=CC2=C(Cl)C=C1C(C3=CC=CC(Cl)=C3)NC4=NC=CC=C4
Molecular Formula
C21H15Cl2N3O
Molecular Weight
396.27
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
TCL1A (T-Cell Leukemia/Lymphoma 1A, TCL1) (MaxLight 405) discontinued
